Calliditas Therapeutics recently released data from a decisive Phase 2 trial testing the efficacy of setanaxib, the company’s primary NOX enzyme inhibitor. This experimental treatment, used in combination with pembrolizumab, was tested on patients with squamous cell carcinoma located in the head and neck. The collected data showed a significant increase in progression-free survival rates. The overall chances of survival also rose remarkably. These changes in tumor biology align with the anticipated effects of setanaxib.
Calliditas Therapeutics has also begun additional clinical trials testing the effect of setanaxib. The outcome of their Phase 2 trial in primary biliary cholangitis is anticipated by the third quarter of 2024. The Phase 2 trial, led by investigators, is expected to provide initial data about idiopathic pulmonary fibrosis by the fourth quarter of 2024.
To stay updated on more health-related news, visit rttnews.com.
